Lack of Pharmacokinetic and Pharmacodynamic Interaction Between Pantoprazole and Glibenclamide in Humans

The new H+/K+-ATPase inhibitor pantoprazole potently inhibits gastric acid secretion and is highly effective in the treatment of peptic ulceration. Pantoprazole is metabolised in the liver by CYP2C19 and CYP3A4. The sulfonylurea glibenclamide, widely used for treatment of type 2 diabetes mellitus, is metabolised mainly in the liver by CYP3A. As substituted benzimidazoles may potentially interact with the cytochrome P450 system, the influence of pantoprazole on the pharmacokinetics and pharmacodynamics of glibenclamide was investigated. 18 healthy male volunteers completed a randomised crossover study according to protocol. They received 40mg pantoprazole or placebo for 5 days each, and concomitantly 3.5mg glibenclamide (micronised preparation) on the 5th day. Additionally, 40mg pantoprazole alone was administered on a separate day. Glibenclamide, pantoprazole, glucose and insulin serum concentrations were measured.